ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Vaccination of CML patients with a BCR-ABL breakpoint peptide vaccine in QS-21 adjuvant was safe, well tolerated and was capable of inducing specific immune responses to the fusion peptides [41].